Share This Article:

Mugwort (Artemisia vulgaris, Artemisia douglasiana, Artemisia argyi) in the Treatment of Menopause, Premenstrual Syndrome, Dysmenorrhea and Attention Deficit Hyperactivity Disorder

Full-Text HTML XML Download Download as PDF (Size:193KB) PP. 116-123
DOI: 10.4236/cm.2012.33019    6,598 Downloads   12,166 Views   Citations

ABSTRACT

Mugwort has many traditional uses around the world. The Chumash Indians of California use it to treat imbalances that women may suffer such as premenstrual syndrome, dysmenorrhea and menopausal symptoms. The plant contains a sesquiterpene that appears to work through a serotonergic mechanism and may be beneficial for women. Mugwort therapy is safer for menopausal women than hormone replacement therapy. Children affected by attention deficit hyperactivity disorder benefit from mugwort therapy. There is no doubt that mugwort therapy is safer for these children than methylphenidate or amphetamine.

Cite this paper

J. Adams, C. Garcia and G. Garg, "Mugwort (Artemisia vulgaris, Artemisia douglasiana, Artemisia argyi) in the Treatment of Menopause, Premenstrual Syndrome, Dysmenorrhea and Attention Deficit Hyperactivity Disorder," Chinese Medicine, Vol. 3 No. 3, 2012, pp. 116-123. doi: 10.4236/cm.2012.33019.

References

[1] R. Grainger Bisset, “Max Wichtl Herbal Drugs and Phytopharmaceuticals a Handbook for Practice on a Scientific Basis,” CRC Press, Boca Raton, 2000.
[2] M. Moran, M. McAlexander, T Biro and A Szallasi, “Transient Receptor Potential Channels as Therapeutic Targets,” Nature Reviews, Vol. 10, 2011, pp. 601-620. doi:10.1038/nrd3456
[3] H. Xu, N. Blair and D. Clapham, “Camphor Activates and Strongly Desensitizes the Transient Receptor Potential Vanilloid Subtype 1 Channel in Vanilloid-Independent Mechanism,” Journal of Neuroscience, Vol. 25, No. 39, 2005, pp. 8924-8937. doi:10.1523/JNEUROSCI.2574-05.2005
[4] A. Martinez, M. Gonzalez-Trujano, E. Aguirre-Hernandez, J. Moreno, M. Soto-Hernandez and F. Lopez-Munoz, “Antinociceptive Activity of Tilia americana var. mexicana Inflorescences and Quercetin in the Formalin Test and in an Arthritic Pain Model in Rats,” Neuropharmacology, Vol. 56, No. 2, 2009, pp. 564-571. doi:10.1016/j.neuropharm.2008.10.010
[5] A. Martinez, M. Gonzalez-Trujano, F. Pellicer, F. Lo-pez-Munoz and A. Navarette, “Antinociceptive Effect and GC/MS Analysis of Rosmarinus officinalis L. Essential Oil from Its Aerial Parts,” Planta Medica, Vol. 75, No. 5, 2009, pp. 508-511. doi:10.1055/s-0029-1185319
[6] C. Liapi, G. Anifandis, I. Chinou, A. Kourounakis, S. Theodosopoulos and P. Galanopoulou, “Antinociceptive Properties of 1,8-Cineole and Beta-Pinene, from the Essential Oil of Eucalyptus camaldulensis Leaves, in Rodents,” Planta Medica, Vol. 73, No. 12, 2007, pp. 1247-1254. doi:10.1055/s-2007-990224
[7] R. Granger, E. Campbell and G. Johnston, “(+)- and (?)-Borneol: Efficacious Positive Modulators of GABA Action at Human Recombinant α1β2γ2L GABAA Receptors,” Biochemical Pharmacology, Vol. 69, No. 7, 2005, pp. 1101-1111. doi:10.1016/j.bcp.2005.01.002
[8] K. Hold, N. Sirisoma, T. Ikeda, T. Narahashi and J. Casida, “Alpha-Thujone (the Active Component of Absinthe): Gamma-Aminobutyric Acid Type A Receptor Modulation and Metabolic Detoxification,” Proceedings of the National Academy of Science USA, Vol. 97, No. 8, 2000, pp. 4417-4418. doi:10.1073/pnas.070042397
[9] J. Vriens, G. Appendino and B. Nilius, “Pharmacology of Vanilloid Transient Receptor Potential Cation Channels,” Molecular Pharmacology, Vol. 75, No. 6, 2009, pp. 1262-1279. doi:10.1124/mol.109.055624
[10] A. Vogt-Eisele, K. Weber, M. Sherkheli, G. Vielhaber, J. Panten, G. Gisselmann and H. Hatt, “Monoterpenoid Agonists of TRPV3,” British Journal of Pharmacology, Vol. 151, No. 4, 2007, pp. 530-540. doi:10.1038/sj.bjp.0707245
[11] A. Basbaum, D. Bautista, G. Scherrer and D. Julius,” Cellular and Molecular Mechanisms of Pain,” Cell, Vol. 139, No. 2, 2009, pp. 267-284. doi:10.1016/j.cell.2009.09.028
[12] T. Ishida, “Biotransformation of Terpenoids by Mammals, Microorganisms, and Plant-Cultured Cells,” Chemical Biodiversity, Vol. 2, No. 5, 2005, pp. 569-590. doi:10.1002/cbdv.200590038
[13] C. Lin, C. Chen, T. Lin, J. Tung and S. Wang, “Anti-Inflammation Activity of Fruit Essential Oil from Cinnamomum insularimontanum Hayata,” Bioresource Technology, Vol. 99, No. 18, 2008, pp. 8783-8787. doi:10.1016/j.biortech.2008.04.041
[14] Y. Tung, M. Chua, S. Wang and S. Chang, “Anti-Inflammation Activities of Essential Oil and Its Constituents from Indigenous Cinnamon (Cinnamomum osmophloeum) Twigs,” Bioresource Technology, Vol. 99, No. 9, 2008, pp. 3908-3913. doi:10.1016/j.biortech.2007.07.050
[15] A. Ruikar, A. Misar, R. Jadhav, S. Rojatkar, A. Mujumdar, V. Puranik and N. Deshpande, “Sesquiterpene Lactone, a Potent Drug Molecule from Artemisia Pallens Wall with Anti-Inflammatory Activity,” Arzneimittel Forschung, Vol. 61, No. 9, 2011, pp. 510-514. doi:10.1055/s-0031-1296236
[16] L. Fonseca, S. Dadarkar, A. Lobo, P. Mishra, A. Thakkar, S. Chandrababu and M. Padigaru, “NF-kappaB Mediated Anti-Inflammatory Activity of the Sesquiterpene Lactone 7-Hydroxyfrullanolide,” European Journal of Pharmacology, Vol. 657, No. 1-3, 2011, pp. 41-50. doi:10.1016/j.ejphar.2011.01.050
[17] Y. Li, Y. Xian, S. Ip, Z. Su, J. Su, J. He, Q. Xie, X. Lai and Z. Lin, “Anti-Inflammatory Activity of Patchouli Alcohol Isolated from Pogostemonis Herba in Animal Models,” Fitoterapia, Vol. 82, No. 8, 2011, pp. 1295- 1301. doi:10.1016/j.fitote.2011.09.003
[18] C. Rummel, R. Gerstberger, J. Roth and T. Hubschle, “Parthenolide Attenuates LPS-Induced Fever, Circulating Cytokines and Markers of Brain Inflammation in Rats,” Cytokine, Vol. 56, No. 3, 2011, pp. 739-748. doi:10.1016/j.cyto.2011.09.022
[19] S. Kim, E. Jung, J. Kim, Y. Park, J. Lee and D. Park, “Inhibitory Effects of (?)-Alpha-Bisabolol on LPS Induced Inflammatory Response in RAW264.7 Macrophages,” Food and Chemical Toxicology, Vol. 49, No. 10, 2011, pp. 2580-2585. doi:10.1016/j.fct.2011.06.076
[20] A. Hensel, M. Maas, J. Sendker, M. Lechtenberg, F. Petereit, A. Deters, T. Schmidt and T. Stark, “Eupatorium perfoliatum L.: Phytochemistry, Traditional Use and Current Applications,” Journal of Ethnopharmacology, Vol. 138, No. 3, 2011, pp. 641-651. doi:10.1016/j.jep.2011.10.002
[21] X. Cheng, Q. Zeng, J. Ren, J. Qin, S. Zhang, Y. Shen, J. Zhu, F. Zhang, R. Chang, Y. Zhu, W. Zhang and H. Jin, “Sesquiterpene lactones from Inula falconeri, a Plant Endemic to the Himalayas, as Potential Anti-Inflammatory Agents,” European Journal of Medicinal Chemistry, Vol. 46, No. 11, 2011, pp. 5408-5415. doi:10.1016/j.ejmech.2011.08.047
[22] R. Landberg, Q. Sun, E. Rimm, A. Cassidy, A. Scalbert, C. Mantzoros, F. Hu and R. van Dam, “Selected Dietary Flavonoids Are Associated with Markers of Inflammation and Endothelial Dysfunction in Women,” Journal of Nutrition, Vol. 141, No. 4, 2011, pp. 618-625. doi:10.3945/jn.110.133843
[23] G. Autore, L. Rastrelli, M. Lauro, S. Marzocco, R. Sorrenetino, U. Sorrentino, A. Pinto and R. Aquino, “Inhibition of Nitric Oxide Synthase Expression by a Methanolic Extract of Crescentia alata and Its Derived Flavonols,” Life Science, Vol. 70, No. 5, 2001, pp. 523-534. doi:10.1016/S0024-3205(01)01425-4
[24] W. Kwak, T. Moon, C. Lin, H. Rhyn, H. Jung, E. Lee, D. Kwon, K. Son, H. Kim, S. Kang, M. Murakami, I. Kudo and H. Chang, “Papyriflavolol A from Broussonetia papyrfera Inhibits the Passive Cutaneous Anaphylaxis Reaction and Has a Secretory Phospholipase A2 Inhibitory Activity,” Biological and Pharmaceutical Bulletin, Vol. 26, 2003, pp. 299-302. doi:10.1248/bpb.26.299
[25] P. Remberg, L. Bjork, T. Hedner and O. Sterner, “Characteristics, Clinical Effect Profile and Tolerability of a Nasal Spray Preparation of Artemisia abrotanum L. for Allergic Rhinitis,” Phytomedicine, Vol. 11, No. 1, 2004, pp. 36-42. doi:10.1078/0944-7113-00350
[26] T. Barros, L. de Freitas, H. Filho, X. Nunes, A. Giulietti, G. de Souza, R. dos Santos, M. Soares and C. Villarreal, “Antinociceptive and Anti-Inflammatory Properties of 7-Hydroxycoumarin in Experimental Animal Models: Potential Therapeutic for the Control of Inflammatory Chronic Pain,” Journal of Pharmacy and Pharmacology, Vol. 62, No. 2, 2010, pp. 205-213. doi:10.1211/jpp.62.02.0008
[27] M. Kurokawa, W. Watanabe, T. Shimizu, R. Sawamura and K. Shiraki, “Modulation of Cytokine Production by 7-Hydroxycoumarin in Vitro and Its Efficacy against Influenza Infection in Mice,” Antiviral Research, Vol. 85, No. 2, 2010, pp. 373-380. doi:10.1016/j.antiviral.2009.11.001
[28] B. Ramesh and K. Pugalendi, “Antihyperglycemic Effect of Umbelliferone in Streptozotocin Diabetic Rats,” Journal of Medicinal Food, Vol. 9, No. 4, 2006, pp. 562-566. doi:10.1089/jmf.2006.9.562
[29] B. Ramesh and K. Pugalendi, “Antihyperlipidemic and Antidiabetic Effects of Umbelliferone in Streptozotocin Diabetic Rats,” Yale Journal of Biology and Medicine, Vol. 78, No. 4, 2005, pp. 189-196.
[30] S. Pan, Y. Huang, J. Guh, C. Peng and C. Teng, “Esculetin Inhibits Ras Mediated Cell Proliferation and Attenuates Vascular Restenosis Following Angioplasty in Rats,” Biochemical Pharmacology, Vol. 65, No. 11, 2003, pp. 1897-1905. doi:10.1016/S0006-2952(03)00161-8
[31] K. Matsunaga, N. Yoshimi, Y. Yamada, M. Shimizu, K. Kawabata, Y. Ozawa, A. Hara and H. Mori, “Inhibitory Effects of Nambumetone, a Cyclooxygenase 2 Inhibitor, and Esculetin, a Lipoxygenase Inhibitor, on N-Methyl-N-Nitorosourea Induced Mammary Carcinogenesis in Rats,” Japanese Journal of Cancer Research, Vol. 89, No. 5, 1998, pp. 496-501. doi:10.1111/j.1349-7006.1998.tb03289.x
[32] M. Marshall, J. Mohler, K. Edmonds, B. Williams, K. Butler, M. Ryles, L. Weiss, D. Urban, A. Bueschen and M. Markiewicz, “An Updated Review of the Clinical Development of Coumarin (1,2-Benzopyrone) and 7-Hydroxycoumarin,” Journal of Cancer Research and Clinical Oncology, Vol. 120, No. Supplement 1, 1994, pp. S39-S42. doi:10.1007/BF01377124
[33] L. Kapoor, “CRC Handbook of Ayurvedic Medicinal Plants,” CRC Press, Boca Raton, 1990.
[34] J. D. Adams, C. Garcia and E. J. Lien, “A Comparison of Chinese and American Indian (Chumash) Medicine,” Evidence-Based Complementary and Alternative Medicine, Vol. 7, No. 2, 2008, pp. 219-225.
[35] W. Tang and G. Eisenbrand, “Handbook of Chinese Medicinal Plants,” Vol. 1, Wiley VCH, Weinheim, 2011.
[36] C. Garcia and J. D. Adams, “Healing with Medicinal Plants of the West—Cultural and Scientific Basis for Their Use,” 2nd Edition, Abedus Press, La Crescenta, 2009.
[37] J. D. Adams and C. Garcia, “Women’s Health among the Chumash,” Evidence Based Comparative and Alternative Medicine, Vol. 3, No. 1, 2006, pp. 125-131. doi:10.1093/ecam/nek021
[38] J. Amiel, S. Mathew, A. Garakani, A. Neumeister and D. Charney, “Neurobiology of Anxiety Disorders,” In: A. Schatzberg and C. Nemeroff, Eds., Textbook of Psychopharmacology, The American Psychiatric Publishing Co, Washington DC, 2009, pp. 965-985.
[39] A. Penissi, L. Mariani, M. Souto, J. Guzman and R. Piezzie, “Changes in Gastroduodenal 5-Hydroxytryptamine Containing Cells Induced by Dehydroleucodine,” Cells Tissues Organs, Vol. 166, No. 3, 2000, pp. 259-266. doi:10.1159/000016739
[40] A. Penissi, M. Rudolph, M. Villar, R. Coll, T. Fogal and R. Piezzi, “Effect of Dehydroleucodine on Histamine and Serotonin Release from Mast Cells in the Isolate Mouse Jejunum,” Inflammation Research, Vol. 52, No. 5, 2003, pp. 199-205.
[41] A. Penissi, M. Vera, M. Mariani, M. Rudolph, J. Cenal, J. de Rosas, T. Fogal, C. Tonn, L. Favier, O. Giordano and R. Piezzi, “Novel Anti-Ulcer α,β-Unsaturated Lactones Inhibit Compound 48/80 Induced Mast Cell Degranulation,” European Journal of Pharmacology, Vol. 612, No. 1-3, 2009, pp. 122-130. doi:10.1016/j.ejphar.2009.03.052
[42] G. Rodriguez, L. Pestchanker, M. Pestchanker, O. Giordano, “Guaianolides and Other Constituents from Artemisia douglasiana,” Phytochemistry, Vol. 29, No. 9, 1990, pp. 3028-3029. doi:10.1016/0031-9422(90)87129-I
[43] L. Jakupovic, V. Chau-Thi, U. Warning, F. Bohlmann and H. Greger, “11b,13-Dihdroguaianolides from Artemisia douglasiana and a Thiophene Acetylene from A. Schmidtiana,” Phytochemistry, Vol. 25, 1986, pp. 1663-1667.
[44] S. Matsueda and T. Geissman, “Sesquiterpene Lactones of Artemisia Species. IV. Douglanine from Artemisia douglasiana Bess,” Tetrahedron Letters, Vol. 8, No. 23, 1967, pp. 2159-2162. doi:10.1016/S0040-4039(00)90788-3
[45] S. Matsueda and T. Geissman, “Sesquiterpene Lactones of Artemisia Species. III. Arglanine from Artemisia douglasiana Bess,” Tetrahedron Letters, Vol. 8, No. 21, 1967, pp. 2013-2015. doi:10.1016/S0040-4039(00)90776-7
[46] F. Bohlmann, N. Ates, J. Jakupovic, R. King and H. Robinson, “Types of Sequiterpenes from Artemisia douglasiana,” Phytochemistry, Vol. 21, No. 11, 1982, pp. 2691-2697. doi:10.1016/0031-9422(82)83100-2
[47] K. Lee, S. Matsueda and T. Geissman, “Sesquiterpene Lactones of Artemisia: New Guaianolides from Fall Growth of A. douglasiana,” Phytochemistry, Vol. 10, No. 2, 1971, pp. 405-410. doi:10.1016/S0031-9422(00)94057-3
[48] K. Meepagala, J. Kuhajek, G. Sturtz and D. Wedge, “Vulgarone B, the Antifungal Constituent in the Steam Distilled Fraction of Artemisia douglasiana,” Journal of Chemical Ecology, Vol. 29, No. 8, 2003, pp. 1771-1780. doi:10.1023/A:1024842009802
[49] T. Guardia, A. Juarez, E. Guerreiro, J. Guzman and L. Pelzer, “Anti-Inflammatory Activity and Effect on Gastric Acid Secretion of Dehydroleucodine Isolated from Artemisia douglasiana,” Journal of Ethnopharmacology, Vol. 88, No. 2-3, 2003, pp. 195-198. doi:10.1016/S0378-8741(03)00211-3
[50] G. Wendel, A. Maria, J. Guzman, O. Giordano and L. Pelzer, “Antidiarrheal Activity of Dehydroleucodine Isolated from Artemisia douglasiana,” Fitoterapia, Vol. 79, No. 1, 2008, pp. 1-5. doi:10.1016/j.fitote.2007.05.006
[51] A. Mahmoud and A. Ahmed, “Alpha-Pinene Type Monoterpenes and Other Constituents from Artemisia suksdorfii,” Phytochemistry, Vol. 67, No. 19, 2006, pp. 2103- 2109. doi:10.1016/j.phytochem.2006.06.013
[52] T. Ohno, A. Nagatsu, M. Nagawa, M. Inoue, Y. Li, S. Minatoguchi, H. Mizukami and H. Fujiwara, “New Sesquiterpene Lactones from Water Extract of the Root of Lindera strychnifolia with Cytotoxicity against Human Small Cell Lung Cancer Cell, SBC-3,” Tetrahedron Letters, Vol. 46, No. 50, 2005, pp. 8657-8660. doi:10.1016/j.tetlet.2005.10.051
[53] H. Xu, N. Blair and D. Clapham, “Camphor Activates and Strongly Desensitizes the Transient Receptor Potential Vanilloid Subtype 1 Channel in Vanilloid-Independent Mechanism,” Journal of Neuroscience, Vol. 25, No. 39, 2005, pp. 8924-8937. doi:10.1523/JNEUROSCI.2574-05.2005
[54] A. Martinez, M. Gonzalez-Trujano, F. Pellicer, F. Lopez-Munoz and A. Navarette, “Antinociceptive Effect and GC/MS Analysis of Rosmarinus officinalis L. Essential Oil from Its Aerial Parts,” Planta Medica, Vol. 75, No. 5, 2009, pp. 508-511. doi:10.1055/s-0029-1185319
[55] C. Liapi, G. Anifandis, I. Chinou, A. Kourounakis, S. Theodosopoulos and P. Galanopoulou, “Antinociceptive Properties of 1,8-Cineole and Beta-Pinene, from the Essential Oil of Eucalyptus camaldulensis Leaves, in Rodents,” Planta Medica, Vol. 73, 2007, pp. 1247-1254. doi:10.1055/s-2007-990224
[56] K. Hold, N. Sirisoma, T. Ikeda, T. Narahashi and J. Casida, “Alpha-Thujone (the Active Component of Absinthe): Gamma-Aminobutyric Acid Type A Receptor Modulation and Metabolic Detoxification,” Proceedings of the National Academy of Science USA, Vol. 97, No. 8, 2000, pp. 4417-4418. doi:10.1073/pnas.070042397
[57] J. Vriens, G. Appendino and B. Nilius, “Pharmacology of Vanilloid Transient Receptor Potential Cation Channels,” Molecular Pharmacology, Vol. 75, No. 6, 2009, pp. 1262-1279. doi:10.1124/mol.109.055624
[58] A. Vogt-Eisele, K. Weber, M. Sherkheli, G. Vielhaber, J. Panten, G. Gisselmann and H. Hatt, “Monoterpenoid Agonists of TRPV3,” British Journal of Pharmacology, Vol. 151, No. 4, 2007, pp. 530-540. doi:10.1038/sj.bjp.0707245
[59] S. Murakami, M. Matsuura, T. Satou, S. Hayashi and K. Koike, “Effects of the Essential Oil from Leaves of Alpinia zerumbet on Behavioral Alterations in Mice,” Natural Product Communications, Vol. 4, No. 1, 2009, pp. 129-132.
[60] T. Umezu, K. Nagano, H. Ito, K. Kosakai, M. Sakaniwa and M. Morita, “Anticonflict Effects of Lavender Oil and Identification of Its Active Constituents,” Pharmacology Biochemistry and Behavior, Vol. 85, No. 4, 2006, pp. 713-721. doi:10.1016/j.pbb.2006.10.026
[61] D. Lachenmeier and M. Uebelacker, “Risk Assessment of Thujone in Foods and Medicines Containing Sage and Wormword—Evidence for a Need of Regulatory Changes?” Regulatory Toxicology and Pharmacology, Vol. 58, No. 3, 2010, pp. 437-443. doi:10.1016/j.yrtph.2010.08.012
[62] F. Napolitano, A. Bonito-Oliva, M. Federici, M. Carta, F. Errico, S. Magara, G. Martella, R. Nistico, D. Centonze, A. Pisani, H. Gu, N. Mercuri and A. Usiello, “Role of Aberrant Striatal Dopamine D1 Receptor/cAMP/Protein Kinase A/DARP32 Signaling in the Paradoxical Calming Effect of Amphetamine,” Journal of Neuroscience, Vol. 30, No. 33, 2010, pp. 11043-11056. doi:10.1523/JNEUROSCI.1682-10.2010
[63] H. Won, W. Mah, E. Kim, J. Kim, E. Hahm, M. Kim, S. Cho, J. Kim, H. Jang, S. Cho, B. Kim, M. Shin, J. Seo, J. Jeong, S. Choi, D. Kim, C. Kang and E. Kim, “GIT1 Is Associated with ADHD in Humans and ADHD-Like Behaviors in Mice,” Nature Medicine, Vol. 17, No. 5, 2011, pp. 566-572. doi:10.1038/nm.2330
[64] R. Gong, C. Ding, J. Hu, Y. Lu, F. Liu, E. Mann, F. Xu, M. Cohen and M. Luo, “Role for the Membrane Receptor Guanylyl Cyclase-C in Attention Deficiency and Hyperactive Behavior,” Science, Vol. 333, No. 6049, 2011, pp. 1642-1646. doi:10.1126/science.1207675
[65] T. Pringsheim T and T. Steeves, “Pharmacological Treatment for Attention Deficit Hyperactivity Disorder (ADHD) in Children with Comorbid Tic Disorders,” Cochrane Data-Base of Systemic Reviews, Vol. 13, No. 4, 2011.
[66] D. Archer, C. Dupont, G. Constantine, J. Pickar and S. Olivier, “Desvenlafaxine for the Treatment of Vasomotor Symptoms Associated with Menopause: A Double Blind, Randomized, Placebo Controlled Trial of Efficacy and Safety,” American Journal of Obstetrics and Gynecology, Vol. 200, No. 3, 2009, pp. 238-248.
[67] D. Deecher, C. Beyer and G. Johnston, “Desvenlafaxine Succinate: A New Serotonin and Norepinephrine Reuptake Inhibitor,” Journal of Pharmacology and Experimental Therapeutics, Vol. 318, No. 2, 2006, pp. 657-665. doi:10.1124/jpet.106.103382
[68] A. Subramanian and the Editorial Board, “Drug Facts and Comparisons,” Wolters Kluwer Health, St Louis, 2009.
[69] D. Butt, M. Lock, J. Lewis, S. Ross and R. Moineddin, “Gabapentin for the Treatment of Menopausal Hot Flashes: A Randomized Controlled Trial,” Menopause, Vol. 15, 2008, pp. 310-318. doi:10.1097/gme.0b013e3180dca175
[70] D. Parker, J. Ong, V. Marino and D. Kerr, “Gabapentin Activates Presynaptic GABAB Heteroreceptors in Rat Cortical Slices,” European Journal of Pharmacology, Vol. 495, No. 2-3, 2004, pp. 137-143. doi:10.1016/j.ejphar.2004.05.029
[71] K. Mahmud, “Natural Hormone Therapy for Menopause,” Gynecology and Endocrinology, Vol. 26, No. 2, 2010, pp. 81-85. doi:10.3109/09513590903184134
[72] P. Bernstein and G. Pohost, “Progesterone, Progestins and the Heart,” Reviews in Cardiovascular Medicine, Vol. 11, No. 3, 2010, pp. e141-149.
[73] A. Howell and G. Evans, “Hormone Replacement Therapy and Breast Cancer,” Recent Results in Cancer Research, Vol. 88, 2011, pp.115-124.
[74] E. Hogervorst, K. Yaffe, M. Richards and F. Huppert, “Hormone Replacement Therapy to Maintain Cognitive Function in Women with Dementia,” Cochrane Database Systematic Review, Vol. 1, 2010.
[75] M. Craig, P. Maki and D. Murphy, “The Women’s Health Initiative Memory Study: Findings and Implications for Treatment,” Lancet Neurology, Vol. 4, No. 3, 2005, pp. 190-194.

  
comments powered by Disqus

Copyright © 2017 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.